25 July 2024
25 July 2024
The upfront purchase price for the investments in the two companies totals approximately $1.2bn.
The voluntary correction is intended for the FreeStyle Libre 3 sensors distributed in the first half of May 2024.
The ASSURE wearable system is designed to offer autonomous detection and defibrillation for ventricular arrhythmias.
The company plans to use the funds to conduct an early feasibility study and a pivotal trial for its transfemoral tricuspid heart valve replacement system, Topaz.
The device operates by generating personalised acoustic vibrations.
3D printing will be extensively adopted across various aspects of healthcare in the next ten years.
Late-breaking data from the Zoom reperfusion system was presented at the Society of NeuroInterventional Surgery (SNIS) 2024.
The company is targeting US expansion, in addition to consolidating UK and European markets.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
